KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Non-Current Deffered Revenue: 2009-2017

Historic Non-Current Deffered Revenue for Vertex Pharmaceuticals (VRTX) over the last 8 years, with Dec 2017 value amounting to $1.7 million.

  • Vertex Pharmaceuticals' Non-Current Deffered Revenue fell 73.97% to $1.7 million in Q4 2017 from the same period last year, while for Dec 2017 it was $1.7 million, marking a year-over-year decrease of 73.97%. This contributed to the annual value of $1.7 million for FY2017, which is 73.97% down from last year.
  • According to the latest figures from Q4 2017, Vertex Pharmaceuticals' Non-Current Deffered Revenue is $1.7 million, which was down 40.83% from $2.9 million recorded in Q3 2017.
  • Vertex Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $90.3 million for Q1 2013, and its period low was $1.7 million during Q4 2017.
  • In the last 3 years, Vertex Pharmaceuticals' Non-Current Deffered Revenue had a median value of $7.0 million in 2016 and averaged $9.7 million.
  • Data for Vertex Pharmaceuticals' Non-Current Deffered Revenue shows a maximum YoY plummeted of 73.97% (in 2017) over the last 5 years.
  • Over the past 5 years, Vertex Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $49.5 million in 2013, then tumbled by 43.78% to $27.8 million in 2014, then crashed by 65.07% to $9.7 million in 2015, then slumped by 31.73% to $6.6 million in 2016, then tumbled by 73.97% to $1.7 million in 2017.
  • Its last three reported values are $1.7 million in Q4 2017, $2.9 million for Q3 2017, and $4.2 million during Q2 2017.